0001080014 2026-02-13 0001080014 2025-01-01 2025-12-31 0001080014 2025-06-30 shares iso4217:USD true 0001080014 FY 10-K/A true 2025-12-31 --12-31 2025 false 000-30319 INNOVIVA, INC. DE 94-3265960 1350 Old Bayshore Highway, Suite 400 Burlingame CA 94010 650 238-9600 Common Stock $0.01 Par Value INVA NASDAQ Yes No Yes Yes Large Accelerated Filer false false true false false 1260000000 74073646 DOCUMENTS INCORPORATED BY REFERENCE Specified portions of the registrant’s definitive Proxy Statement to be issued in conjunction with the registrant’s 2026 Annual Meeting of Stockholders, which is expected to be filed not later than 120 days after the registrant’s fiscal year ended December 31, 2025, are incorporated by reference into Part III of this Annual Report. Except as expressly incorporated by reference, the registrant’s Proxy Statement shall not be deemed to be a part of this Annual Report on Form 10-K/A. This Amendment No. 1 on Form 10-K/A (the “Amendment”) amends the Annual Report on Form 10-K of Innoviva, Inc. (the “Company”) for the year ended December 31, 2025, originally filed on February 25, 2026 (the “Original Filing”), is being filed pursuant to and in compliance with the time requirements of Rule 3-09 of Regulation S-X, to amend Item 15, Exhibits and Financial Statement Schedules, to include the Audited Consolidated Financial Statements of Armata Pharmaceuticals, Inc. (“Armata”) at December 31, 2025 and 2024 and for the years then ended and the Consent of Ernst & Young LLP Independent Registered Public Accounting Firm of Armata as Exhibit 99.1 and Exhibit 23.3, respectively. These exhibits were not available at the time of the Original Filing. Additional information on the Audited Consolidated Financial Statements of Armata for the year ended December 31, 2023 can be found in the Company’s Amendment No. 1 on Form 10-K/A for the year ended December 31, 2024, filed on March 24, 2025, and is incorporated herein by reference. Deloitte & Touche LLP San Jose, CA 34